

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

APPOINTMENT OF EXECUTIVE DIRECTOR

Reference is made to the announcement on 26 August 2014 regarding the proposed appointment of Mr. Yang Daihong (“**Mr. Yang**”) as an Executive Director. At the first extraordinary general meeting for the year 2014 (the “**Extraordinary General Meeting**”) of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”) held on 24 October 2014, Mr. Yang was appointed as Executive Director of the eighth session of the board of directors of the Company (the “**Board**”), whose duty term is from the date of the approval for the related resolution of the appointment at the Extraordinary General Meeting (i.e. 24 October 2014) to the expiration of the eighth session of the Board.

BIOGRAPHICAL DETAILS OF THE NEWLY APPOINTED EXECUTIVE DIRECTOR

Mr. Yang Daihong (楊代宏先生), aged 48, is currently our vice president, a pharmaceutical engineer and a licenced pharmacist. From 2000 to 2002, Mr. Yang attended a course in enterprise management organised by Business College in Sun Yat-Sen University (中山大學). Mr. Yang obtained qualifications as a pharmaceutical engineer and a licenced pharmacist. From 1999 to 2009, Mr. Yang was the deputy factory manager and factory manager of Livzon Group Livzon Pharmaceutical Factory (麗珠集團麗珠製藥廠). Mr. Yang has been our vice president from May 2006 to present.

As of the date of this announcement, Mr. Yang has not held any current directorship in other listed companies and in the three years preceding the date of this announcement. He did not have any relationship with any other directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company, and did not have any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Mr. Yang is entitled to an annual director fee of RMB72,000, an annual salary of RMB550,000 plus discretionary bonus during his tenure. Such fee, salary and bonus are determined with reference to his duties and responsibilities within the Company, the Company's remuneration policy and the market salary range for the positions.

Save as disclosed above, there are no other matters needed to be brought to the attention of the shareholders of the Company in relation to the abovementioned new appointment of director, and there is no other information required to be disclosed pursuant to the provisions of Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board

麗珠醫藥集團股份有限公司

Livzon Pharmaceutical Group Inc. *

Yang Liang

Company Secretary

Zhuhai, China

24 October 2014

As at the date of this announcement, the Executive Directors of the Company are Mr. Tao Desheng (Vice Chairman and President), Mr. Fu Daotian (Vice President) and Mr. Yang Daihong (Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Qiu Qingfeng and Mr. Zhong Shan; and the Independent Non-Executive Directors of the Company are Mr. Xu Yanjun, Mr. Yang Bin, Mr. Guo Guoqing, Mr. Wang Xiaojun and Mr. Yu Xiong.

* *For identification purpose only*